Clinical Trials on Malignant Peripheral Nerve Sheath Tumor
Total 9571 results
-
University Hospital TuebingenGerman Research FoundationCompleted
-
AstraZenecaCompleted
-
Cytos Biotechnology AGCompletedMalignant MelanomaSwitzerland
-
Bristol-Myers SquibbCompletedMalignant MelanomaUnited States
-
SentoClone ABUnknownMalignant MelanomaSweden
-
Royal Marsden NHS Foundation TrustUnknown
-
University Hospital TuebingenCompletedMalignant MelanomaGermany
-
Cytos Biotechnology AGCompletedMalignant MelanomaSwitzerland
-
Washington University School of MedicineNational Institute of Neurological Disorders and Stroke (NINDS)RecruitingHealthy | Peripheral Nerve Injury Upper LimbUnited States
-
St. Jude Children's Research HospitalCompletedLymphoma | Neuroblastoma | High-risk TumorUnited States
-
Ricardo L. Carrau, MDWithdrawnEsthesioneuroblastoma, OlfactoryUnited States
-
Markus JoergerRecruiting
-
Assistance Publique - Hôpitaux de ParisNational Cancer Institute (NCI)Recruiting
-
Reata, a wholly owned subsidiary of BiogenWithdrawn
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)TerminatedMelanoma | Malignant Melanoma
-
Hoffmann-La RocheCompletedA Pharmacokinetic and Metabolism Study of 14C-labeled RO5185426 on Patients With Metastatic MelanomaMalignant MelanomaSwitzerland
-
Oslo University HospitalActive, not recruitingMalignant MelanomaNorway
-
Ultimovacs ASAActive, not recruitingMalignant MelanomaUnited States
-
Abramson Cancer Center of the University of PennsylvaniaCompletedMalignant MelanomaUnited States
-
Hoffmann-La RocheCompletedMalignant MelanomaUnited States, Spain, Hungary, Israel, United Kingdom, Australia, Austria, Belgium, Czechia, France, Germany, Italy, Netherlands, Russian Federation, Sweden, Switzerland, Canada, New Zealand, Norway
-
Bristol-Myers SquibbMedarex; Ono Pharma USA IncCompleted
-
Medical University of GrazCompleted
-
Prof. Dr. med. Dirk SchadendorfTerminatedMalignant MelanomaGermany
-
Immunocore LtdTerminated
-
Genentech, Inc.Completed
-
Immunocore LtdCompletedMalignant MelanomaUnited Kingdom, United States
-
CelgeneUniversity of ArizonaCompletedMalignant MelanomaCanada, United States, Australia, United Kingdom, France, Italy, Spain, Germany, Netherlands
-
Hoffmann-La RocheCompleted
-
Universitair Ziekenhuis BrusselCompleted
-
Hoffmann-La RocheCompleted
-
Hadassah Medical OrganizationUnknown
-
Merck Sharp & Dohme LLCTerminated
-
Hoffmann-La RocheCompletedMalignant MelanomaItaly, United Kingdom, Belgium, Poland, Netherlands, Germany, Austria, Czechia, Ireland, Sweden
-
CelgeneNYU Langone Health; Syneos Health; Celerion; ApoCell, Inc.CompletedMalignant MelanomaUnited States
-
Hoffmann-La RocheCompletedMalignant MelanomaUnited States
-
Hoffmann-La RocheCompletedMalignant MelanomaUnited States, Australia
-
H. Lee Moffitt Cancer Center and Research InstituteNational Gene Vector LaboratoryCompletedMalignant MelanomaUnited States
-
Genentech, Inc.CompletedMalignant MelanomaUnited States, Australia
-
Hoffmann-La RocheTerminatedMalignant MelanomaUnited States, France, Australia, United Kingdom, Italy, Spain, Germany, Israel, Poland, Slovakia
-
Oslo University HospitalCompleted
-
James Graham Brown Cancer CenterUniversity of LouisvilleCompleted
-
Yonsei UniversityCompleted
-
SciBase ABCompleted
-
Astellas Pharma IncOSI Pharmaceuticals; Cell PathwaysTerminated
-
AmpliMed CorporationCompletedMalignant MelanomaUnited States
-
Eli Lilly and CompanyMemorial Sloan Kettering Cancer CenterCompleted
-
NeoPlas InnovationWithdrawnMelanoma | Malignant MelanomaUnited States
-
Cytos Biotechnology AGCompletedMalignant MelanomaSwitzerland
-
Northern California Melanoma CenterBayer; Melanoma Research InstituteCompleted
-
Titan PharmaceuticalsTerminated